<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Hepatol</journal-id><journal-id journal-id-type="publisher-id">WJH</journal-id><journal-title-group><journal-title>World Journal of Hepatology</journal-title></journal-title-group><issn pub-type="epub">1948-5182</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6206158</article-id><article-id pub-id-type="pmid">30386459</article-id><article-id pub-id-type="other">jWJH.v10.i10.pg662</article-id><article-id pub-id-type="doi">10.4254/wjh.v10.i10.662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="84248" pm="."><plain>Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Cheng-Jie</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zhi-Gao</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Guan-Dou</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Biao</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Song-Qing</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China. <email>dr_hesongqing@163.com</email></aff></contrib></contrib-group><author-notes><fn><p><text><SENT sid="84249" pm="."><plain>Author contributions: Lin CJ and Hu ZG contributed equally to this work; He SQ designed research; Lin CJ, Hu ZG and Yuan GD searched the relevant literatures; and Lin CJ wrote the review; Lei B and He SQ revised the review. <p><text><SENT sid="84250" pm="."><plain>Supported by State Key Program of National Natural Science Foundation of China, No. 8143000311; National Natural Science Foundation of China, No. 81660103 and No. 81771674; 111 Project, No. D17011; Guangxi BaGui Scholars; the Natural Science Foundation of Guangxi Province, No. 2015GXNSFFA139004. <p><text><SENT sid="84251" pm="."><plain>Correspondence to: Song-Qing He, PhD, Chief Doctor, Professor, Research Professor, Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. dr_hesongqing@163.com <p><text><SENT sid="84252" pm="."><plain>Telephone: +86-771-5356568 </fn></author-notes><pub-date pub-type="ppub"><day>27</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2018</year></pub-date><volume>10</volume><issue>10</issue><fpage>662</fpage><lpage>669</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>26</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="84253" pm="."><plain>The complement system is a key component of the body’s immune system. When abnormally activated, this system can induce inflammation and damage to normal tissues and participate in the development and progression of a variety of diseases. In the past, many scholars believed that alcoholic liver disease (ALD) is induced by the stress of ethanol on liver cells, including oxidative stress and dysfunction of mitochondria and protease bodies, causing hepatocyte injury and apoptosis. Recent studies have shown that complement activation is also involved in the genesis and development of ALD. This review focuses on the roles of complement activation in ALD and of therapeutic intervention in complement-activation pathways. We intend to provide new ideas on the diagnosis and treatment of ALD. </p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Alcoholic liver disease</kwd><kwd>Complement system proteins</kwd><kwd>Complement regulator</kwd><kwd>Liver cells</kwd><kwd>Hepatocyte injury</kwd></kwd-group></SecTag></article-meta></front><body><p><text><SENT sid="84259" pm="."><plain>Core tip: In this review, we cited evidence that the complement system is involved in the pathogenesis of each stage of alcoholic liver disease (ALD) that include fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis, and we also summarized the complement regulation in ALD. We intend to provide new ideas on the treatment of ALD. <SecTag type="INTRO"><sec><title><text><SENT sid="84261" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="84262" pm="."><plain>Liver disease caused by long-term excessive ethanol drinking is a major cause of chronic liver disease. As the global incidence of alcoholic liver disease (ALD) increases year by year, it has become a serious threat to human health. Almost all heavy drinkers have fatty liver, 10%-20% of which develop into alcoholic hepatitis, cirrhosis, and even hepatocellular carcinoma[1]. </plain></SENT>
<SENT sid="84265" pm="."><plain>Exploration of the mechanisms of alcohol-induced liver injury and repair is extremely important in developing methods for preventing and treating ALD. <p><text><SENT sid="84266" pm="."><plain>The complement system plays an important beneficial role in the immune system: Complement activation promotes target-cell lysis, with the associated elimination of exogenous pathogens. Yet, the complement system is a “double-edged sword”, as the excessive activation of complement can induce inflammation and lead to autoimmune diseases, such as autoimmune kidney disease, glomerular nephritis, acute lung injury, and others[2-5]. </plain></SENT>
<SENT sid="84268" pm="."><plain>Most plasma complement components are synthesized in liver cells. Thus, the liver becomes the main target of damage by complement activation[6-8]. </plain></SENT>
<SENT sid="84270" pm="."><plain>This connection is likely due to the direct effects of alcohol that activate complement, but not because the liver is a major producer of complement proteins. Several studies have illustrated that complement activation is involved in the development of ALD[8-14] (Table 1). <SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="84272" pm="."><plain>Important publications on complement in alcoholic liver disease </caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84273" pm="."><plain>Study </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84274" pm="."><plain>Complement component </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84275" pm="."><plain>Alcoholic liver disease </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84276" pm="."><plain>Species </plain></SENT>
</text></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84277" pm="."><plain>Järveläinen et al[10] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84278" pm="."><plain>C1, Crry, CD59 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84279" pm="."><plain>Alcohol-induced injury </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84280" pm="."><plain>Rat </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84281" pm="."><plain>Bykov et al[11] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84282" pm="."><plain>C3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84283" pm="."><plain>Liver steatosis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84284" pm="."><plain>Mouse </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84285" pm="."><plain>Pritchard et al[8] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84286" pm="."><plain>C3, C5, DAF </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84287" pm="."><plain>Fatty liver </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84288" pm="."><plain>Mouse </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84289" pm="."><plain>He et al[7] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84290" pm="."><plain>C3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84291" pm="."><plain>Liver steatosis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84292" pm="."><plain>Mouse </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84293" pm="."><plain>Cohen et al[13] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84294" pm="."><plain>C1q </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84295" pm="."><plain>Alcohol-induced injury </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84296" pm="."><plain>Mouse </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84297" pm="."><plain>Wlazlo et al[27] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84298" pm="."><plain>C3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84299" pm="."><plain>Liver steatosis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84300" pm="."><plain>Human </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84301" pm="."><plain>Shen et al[6] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84302" pm="."><plain>C3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84303" pm="."><plain>Alcoholic hepatitis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84304" pm="."><plain>Mouse </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84305" pm="."><plain>Maslowska et al[30] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84306" pm="."><plain>Factor D </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84307" pm="."><plain>Alcoholic hepatitis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84308" pm="."><plain>Mouse </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="84309" pm="."><plain>Crry: Complement receptor 1-related protein y; DAF: Decay accelerating factor. </fn></table-wrap-foot></table-wrap></SecTag></sec></SecTag><sec><title><text><SENT sid="84310" pm="."><plain>METABOLIC PATHWAYS OF ETHANOL </plain></SENT>
</text></title><p><text><SENT sid="84311" pm="."><plain>Most ingested ethanol is absorbed into the blood circulation, and soon reaches each organ of the body. About 90% of the ingested ethanol is metabolized in the liver[15], and most is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase to form acetic acid, which can be used as substrate in the tricarboxylic acid cycle to produce energy. With excessive drinking, the body can activate another metabolic pathway, i.e., the microsomal ethanol oxidation system (MEOS), which catalyzes ethanol mainly by cytochrome P450 2El in Kupffer cells. The MEOS can over produced reactive oxygen species and reactive nitrogen species, which may exceed the body’s antioxidant capacity. Free radicals produced via the MEOS pathway exert a series of toxic effects: Membrane-lipid peroxidation, intracellular protease degeneration, oxidative modification of DNA, and others, which eventually lead to necrosis or apoptosis of hepatocytes[14,16-18]. </plain></SENT>
<SENT sid="84316" pm="."><plain>A small percentage of ethanol is metabolized by fatty acid ethyl ester synthase to produce fatty acid ethyl ester through the non-oxidative pathway. Fatty acid ethyl ester has cytotoxicity, which can further injure the liver and pancreas[19]. </plain></SENT>
<SENT sid="84318" pm="."><plain>Thus the liver becomes the main organ damaged by ethanol. Chronic ethanol exposure results in decreased protease activity in liver cells, imbalance of the liver’s detoxification function, and overproduction of acetaldehyde, thus inducing hepatic oxidative stress and complement activation; all these activities can injure hepatocytes[20]. </sec><sec><title><text><SENT sid="84320" pm="."><plain>COMPLEMENT ACTIVATION PATHWAY </plain></SENT>
</text></title><p><text><SENT sid="84321" pm="."><plain>The complement system consists of more than 30 kinds of proteins with enzyme-like activities which are inherent components, regulatory proteins, and complement receptors. Complement regulatory proteins include plasma soluble factors, membrane binding proteins, homologous restriction factor, and membrane inhibitors of reactive lysis. Because the complement system is involved in inflammation and immune regulation, it plays an important role in regulation of pathophysiological functions[21]. <p><text><SENT sid="84324" pm="."><plain>Complement is activated by three pathways: The classical, mannan-binding lectin (MBL), and alternative pathways. The three pathways start with different mechanisms, but they end with a common terminal pathway, as shown in Figure 1. </plain></SENT>
<SENT sid="84326" pm="."><plain>The classical pathway is the main mechanism of immune responses. In it, C1q identifies immune complexes, followed by the activation of C1r and C1s. Activated C1s cleaves C2 and C4 to form C3 convertase (C4bC2a), which cleaves C3 to form C5 convertase (C4bC2aC3b). </plain></SENT>
<SENT sid="84329" pm="."><plain>In contrast to activation of the classical pathway, activation of the lectin pathway does not depend on immune complexes. In this pathway, the cascade of enzymatic reactions proceeds in this sequence: MBL identifies the pathogens to form MBL-associated serine proteases (MASP1, MASP2); MASP1 directly cleaves C3 to form C3 convertase (C3bBb), MASP2 cleaves C4 and C2 in a manner similar to that of C1s, forming C3 convertase (C4bC2a), which continues to cleave C5 to form C5 convertase (C4bC2aC3b). </plain></SENT>
<SENT sid="84331" pm="."><plain>Thus, this pathway can cross-promote the classical and alternative pathways. The alternative pathway is activated with hydrolysis of C3 into C3(H2O), factor B and factor D, the activation of which is also independent of immune complexes, and participates in the defense mechanisms of the early stage of inflammation[13,22-24]. </plain></SENT>
<SENT sid="84333" pm="."><plain>The above three pathways merge into the terminal pathway, in which C5 convertase cleaves C5 to form C5a and C5b, and C5b combines with C6, C7, C8 and C9 to form the membrane attack complex (MAC). </plain></SENT>
<SENT sid="84334" pm="."><plain>Formation of the MAC leads to cell lysis and induces cells to release inflammatory cytokines. <SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="84335" pm="."><plain>Complement activation pathway and regulation. Three pathways (classical, pathway, mannan-binding lectin, and alternative) are involved in complement activation. Green arrows without a red line indicate the process of complement activation. Green arrows with red line indicate the the process of inhibiting complement activation. MBL: Mannan-binding lectin; MASP: MBL-associated proteases; FB: Factor B; FH: Factor H; FI: Factor I. </caption><graphic xlink:href="WJH-10-662-g001"/></fig></SecTag></sec><sec><title><text><SENT sid="84340" pm="."><plain>COMPLEMENT ACTIVATION IN ALD </plain></SENT>
</text></title><p><text><SENT sid="84341" pm="."><plain>ALD progresses in three distinct stages: Fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis. In this review, we cite evidence that the complement system is involved in the pathogenesis of each of these stages. <sec><title><text><SENT sid="84343" pm="."><plain>Complement activation in alcoholic fatty liver disease </plain></SENT>
</text></title><p><text><SENT sid="84344" pm="."><plain>The liver is the main site of fat metabolism. Disorders of fat metabolism, caused by various factors, can lead to excessive fat accumulation in the liver cells, i.e., fatty liver. Long-term heavy drinking is the main independent risk factor of fatty liver disease[25], but its pathogenesis is not clearly defined. Liu et al[26] found that gut microbiota played a synergistic role in the liver response, and the complement system was suppressed in fatty liver which was partially due to increased blood lactic acid from enriched Lactobacillus. Abnormal complement activation reportedly enhances the sensitivity of steatotic livers to ischemia and reperfusion injury, which leads to the development of fatty liver[27,28]. </plain></SENT>
<SENT sid="84349" pm="."><plain>Järveläinen et al[10] found that deposition of complement C1, C3, and C8 was increased, and the expression of membrane-binding proteins, complement receptor 1-related protein y (Crry), and CD59 was decreased in the liver cells of a mouse ALD model. These findings proved that alcohol-induced complement activation can result in ALD, at least in an experimental model. In a study in mice chronically exposed to ethanol, Cohen et al[13] found that lipid deposition in liver cells as well as values of liver-related serum enzymes (alanine aminotransferase and aspartate amino transferase) increased significantly; various degrees of liver cell apoptosis were also found. Moreover, with knock out of the C1q gene, hepatic steatosis in the mice was significantly decreased[13]. </plain></SENT>
<SENT sid="84353" pm="."><plain>This study illustrated that complement activation could be associated with ethanol-induced hepatic steatosis. <p><text><SENT sid="84354" pm="."><plain>Bykov et al[11] fed C3+/+ and C3-/- mice a high fat and high alcohol diet, respectively, and found that hepatic steatosis and significant increases in triglyceride values occurred in the C3+/+mice, whereas C3-/-mice were protected from ethanol-induced liver injury; research by Stewart et al[9] yielded similar results. <p><text><SENT sid="84355" pm="."><plain>At the complement activation pathways, C3a converted to C3adesAg, C3adesArg which known as acylation stimulating protein had been shown to have lipogenic activity via its receptor C5L2, and promoted triglyceride storage in adipocytes[29,30] It was also found that C3adesArg was involved in the triglyceride metabolism[31]. <p><text><SENT sid="84356" pm="."><plain>Thus, activation of complement C1 and C3 appears to play a significant role in promoting fatty accumulation in the liver. Further definition of the relationship between activated complement C1, C3 and lipid metabolism in the liver may aid in the development of methods for intervention and treatment of alcoholic fatty liver disease. Besides C1 and C3, complement C5 also is involved in lipid metabolism. Bavia et al[32,33] found that the activation of complement C5 by high-dose ethanol exposure can affect the distribution of lipid in liver cells and serum. Less lipid and cholesterol is deposited in hepatocytes of C5- mice than in hepatocytes of C5+mice, and values of IL-17, which are involved in the synthesis and metabolism of lipid and cholesterol, are higher in C5- mice than in C5+mice[34,35]. </plain></SENT>
<SENT sid="84361" pm="."><plain>The above-cited reports indicate that activation of C5 may play a role in the development of alcoholic fatty liver. </sec><sec><title><text><SENT sid="84362" pm="."><plain>Complement activation in alcoholic hepatitis </plain></SENT>
</text></title><p><text><SENT sid="84363" pm="."><plain>ALD has many potential pathogenic factors, such as endotoxin, which may lead to complement activation and deposition in the liver cells. Shen et al[6] found that complement activation was involved in humans with ALD. Cohen et al[13] found that long-term alcohol exposure can lead to apoptosis of liver cells, and the degree of apoptosis is positively correlated with liver injury. However, whether short-term alcohol exposure can cause hepatocyte apoptosis was not known. Further research found that short-term alcohol exposure did not cause hepatocyte apoptosis, but it did promote the deposition of complement C3b and the expression of inflammatory cytokines (tumor necrosis factor and IL6). </plain></SENT>
<SENT sid="84368" pm="."><plain>After the Cq gene was knocked out, the expression of inflammatory cytokines was significantly reduced compared to that in wild-type animals[12,13]. </plain></SENT>
<SENT sid="84369" pm="."><plain>Experiments by Païdassi et al[36] and Lu et al[37] supported these observations. <p><text><SENT sid="84370" pm="."><plain>Complement C5, a core component of the complement activation pathway, is involved in the occurrence and development of alcoholic hepatitis, in addition to fatty liver[6,8,38]. </plain></SENT>
<SENT sid="84371" pm="."><plain>Bavia et al[38] documented this in a hepatitis model induced by alcohol; they found that values of pro-inflammatory cytokines (IL-6, IFN-γ, IL-1β, and others) in B6C5+ mice were significantly higher than those in B6C5- mice, and anti-inflammatory factors (IL10 and IL17) were secreted significantly more in B6C5- mice. These findings illustrated that activated C5 induced the expression of proinflammatory cytokines after alcohol exposure. Up-regulated expression of pro-inflammatory cytokines (IL-6, IFN-γ, IL-1β, and others) aids the body’s defense against pathogenic microorganisms, but it also participates in the pathogenesis of alcoholic fatty liver and alcoholic hepatitis[8,39-41]. </sec><sec><title><text><SENT sid="84374" pm="."><plain>Complement activation in alcoholic hepatic fibrosis </plain></SENT>
</text></title><p><text><SENT sid="84375" pm="."><plain>Intrahepatic inflammatory reaction and a decrease in structural integrity of hepatic sinusoidal endothelial cells after long-term alcohol exposure are important inducements to liver injury. Sinusoidal endothelial cells express C5R1, which is the foundation of C5 activation-induced alcoholic hepatic fibrosis[42]. </plain></SENT>
<SENT sid="84377" pm="."><plain>In recent years, the pathogenesis of alcoholic hepatic fibrosis has attracted worldwide attention , but the cause of the fibrosis is still not fully defined[43-45]. </plain></SENT>
<SENT sid="84378" pm="."><plain>According to published reports[46,47], complement C3, C4 and activation of the MBL pathway are involved in the development of fibrosis. Bavia et al[38] using the mouse model of ALD, found that values of TGF-β, which promotes hepatic fibrosis, were significantly higher in B6C5+ mice than in B6C5- mice[38,48]. </plain></SENT>
<SENT sid="84380" pm="."><plain>Hillebradt et al[49] found that the C5 gene was involved in the regulation of hepatic fibrosis on human chromosome, and further study found that C5- mice had decreased hepatic fibrosis. Thus, the evidence indicates that activation of complement C5 may promote hepatic fibrosis. Exploration of the relationship between complement activation and alcoholic hepatic fibrosis, and of possible intervention in ALD by reversing the progression of hepatic fibrosis in its early stage, seems worthwhile goals. </sec><sec><title><text><SENT sid="84383" pm="."><plain>Complement-induced Kupffer cells activation in ALD </plain></SENT>
</text></title><p><text><SENT sid="84384" pm="."><plain>Kupffer cells, located in liver sinusoids, are an important part of the mononuclear phagocyte system. Alcohol exposure in the early stage can promote apoptosis of Kupffer cells, but longer exposure usually is needed[13,50,51]. </plain></SENT>
<SENT sid="84386" pm="."><plain>Ethanol-induced activation of complement component C1q at the early stage of ALD promotes the release of inflammatory cytokines from Kupffer cells, which further promote alcoholic liver injury[51-56]. </plain></SENT>
<SENT sid="84387" pm="."><plain>Furthermore, Kupffer cells can express C3R and C5R, then induce prostaglandin release and synthesis of pro-inflammatory cytokines[57-60]. </plain></SENT>
<SENT sid="84388" pm="."><plain>However, in certain pathological conditions, activated C5 combines with C5R, inducing the upregulation of fibrinogen on Kupffer cells, an interaction that is believed to lead to hepatic fibrosis[22,61]. </plain></SENT>
<SENT sid="84389" pm="."><plain>In addition, alcohol-induced upregulation of CD14 leads to Kupffer cells combining with lipopolysaccharide, which induces liver damage through the activation of TLR4 in Kupffer cells and inflammatory signaling pathways; these events can further aid in the development of hepatic fibrosis or cirrhosis[62]. </plain></SENT>
<SENT sid="84390" pm="."><plain>Thus, Kupffer cells seem to be extensively involved in the development of ALD[63-66]. </sec></sec><sec><title><text><SENT sid="84391" pm="."><plain>COMPLEMENT REGULATION IN ALD </plain></SENT>
</text></title><p><text><SENT sid="84392" pm="."><plain>Reducing inflammatory reactions by inhibiting amplification of the complement cascade and blocking the combination of complement with the corresponding complement receptors are being pursued worldwide. Excessive activation of complement can be inhibited by self-regulation of the body (Table 2). </plain></SENT>
<SENT sid="84394" pm="."><plain>For example, the complement regulatory protein decay accelerating factor (DAF) can inhibit C3, C5 convertase, thereby inhibiting amplification of the complement cascade. The complement regulatory protein Crry can cooperate with DAF and factor H to accelerate dissociation of C3 and C5 convertase and to cleave C3b and C4b, so that the cells avoid being attacked by autologous complement[67-69]. </plain></SENT>
<SENT sid="84396" pm="."><plain>Deficiency of CD55/DAF and complement regulatory factors aggravate liver injury[8,11], whereas factor H can control the activity and stability of C3 convertase via binding with C3b[70,71]. </plain></SENT>
<SENT sid="84397" pm="."><plain>Also, defects in the factor H gene can cause persistent activation of complement pathways and trigger various diseases[72-75]. </plain></SENT>
<SENT sid="84398" pm="."><plain>By contrast, factor H-related proteins (FHRs), including FHR1-5, can either promote or inhibit complement activation. The degree of complement activation depends on the homeostasis between factor H and FHR[71]. </plain></SENT>
<SENT sid="84400" pm="."><plain>However, the relationship between factor H and ALD has not been clarified and needs further research. McCullough et al[76] found FD-dependent amplification of complement is an adaptive response that promotes hepatic healing and recovery in response to chronic ethanol. In other complement regulatory activities, CD59, protein S and clusterin inhibit the formation of the MAC through limiting the binding of complement C9[77-81]. </plain></SENT>
<SENT sid="84403" pm="."><plain>Membrane cofactor protein (MCP) and factor I can inhibit cells from binding with C3b and C4b[82,83]. <SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="84404" pm="."><plain>Complement regulators </caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84405" pm="."><plain>Type of regulators </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84406" pm="."><plain>Regulators </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84407" pm="."><plain>Functions </plain></SENT>
</text></td></tr></thead><tbody align="center"><tr><td rowspan="2" align="left" colspan="1"><text><SENT sid="84408" pm="."><plain>Complement regulatory protein </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84409" pm="."><plain>DAF/CD55, Crry, FH, FI </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84410" pm="."><plain>Inhibit C3, C5 convertase </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="84411" pm="."><plain>CD59, protein S, clusterin </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84412" pm="."><plain>Inhibit MAC </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84413" pm="."><plain>Complement inhibitor </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84414" pm="."><plain>C1-INH </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84415" pm="."><plain>Inhibit C1r, C1s </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84416" pm="."><plain>Targeted inhibitor </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84417" pm="."><plain>h5G1, 1-ScFv </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84418" pm="."><plain>Inhibit C5 activation </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84419" pm="."><plain>RNA aptamer </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="84420" pm="."><plain>Specifically bind C1q, C5 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="84421" pm="."><plain>DAF: Decay accelerating factor; Crry: Complement receptor 1-related protein y; FH: Factor H; FI: Factor I; MAC: Membrane attack complex. </fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="84422" pm="."><plain>Specific epitope structures of complement, such as anti-complement antibody, complement antisense strand, and complement mutants[84-91] have been invented, with the intent of inhibiting complement activation. In addition, complement inhibitors and RNA aptamer are being used to inhibit progression of complement-related diseases[92,93], and C1-INH and CR1 have been used in the treatment of ALD and other diseases[10]. </sec><SecTag type="CONCL"><sec><title><text><SENT sid="84424" pm="."><plain>CONCLUSION </plain></SENT>
</text></title><p><text><SENT sid="84425" pm="."><plain>Mounting evidence indicates that complement activation is involved in the development of ALD at all its stages - fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis. Moreover, all three pathways of complement activation (classical, MBL, and alternative) promote the development of ALD. Therapeutic strategies, using various measures to inhibit complement activation, might prevent the development of ALD. Thorough understanding of the relationships between complement activation and ALD may aid in developing new approaches for the treatment of ALD. </sec></SecTag></body><back><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="84429" pm="."><plain>Conflict-of-interest statement: All authors have no conflicts of interest to report. </fn><fn><p><text><SENT sid="84430" pm="."><plain>Manuscript source: Invited manuscript </fn><fn><p><text><SENT sid="84431" pm="."><plain>Peer-review started: April 10, 2018 </fn><fn><p><text><SENT sid="84432" pm="."><plain>First decision: May 17, 2018 </fn><fn><p><text><SENT sid="84433" pm="."><plain>Article in press: August 1, 2018 </fn><fn><p><text><SENT sid="84434" pm="."><plain>Specialty type: Gastroenterology and hepatology </fn><fn><p><text><SENT sid="84435" pm="."><plain>Country of origin: China </fn><fn><p><text><SENT sid="84436" pm="."><plain>Peer-review report classification </fn><fn><p><text><SENT sid="84437" pm="."><plain>Grade A (Excellent): 0 </fn><fn><p><text><SENT sid="84438" pm="."><plain>Grade B (Very good): 0 </fn><fn><p><text><SENT sid="84439" pm="."><plain>Grade C (Good): C, C, C, C </fn><fn><p><text><SENT sid="84440" pm="."><plain>Grade D (Fair): 0 </fn><fn><p><text><SENT sid="84441" pm="."><plain>Grade E (Poor): 0 </fn><fn><p><text><SENT sid="84442" pm="."><plain>P- Reviewer: Marcos M, Metin U, Morales-González JA, Kollmann D S- Editor: Ma YJ L- Editor: Ma JY E- Editor: Bian YN </fn></fn-group><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="84443" pm="."><plain>1WarrenKRMurrayMMAlcoholic liver disease and pancreatitis: global health problems being addressed by the US National Institute on Alcohol Abuse and AlcoholismJ Gastroenterol Hepatol201328 Suppl 146 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="84444" pm="."><plain>2YangYMannose Binding Lectin and kidney diseaseInt J Nephrol Urol201030241244 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="84445" pm="."><plain>3BorzaDBGlomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activationMatrix Biol201757-5829931027609404 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="84446" pm="."><plain>4RusskampNFRuemmlerRRoeweJMooreBBWardPABosmannMExperimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxinFASEB J2015293762377225999468 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="84447" pm="."><plain>5ReichhardtMPMeriSIntracellular complement activation-An alarm raising mechanism?Semin Immunol2018 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="84448" pm="."><plain>6ShenHFrenchBALiuHTillmanBCFrenchSWIncreased activity of the complement system in the liver of patients with alcoholic hepatitisExp Mol Pathol20149733834425217811 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="84449" pm="."><plain>7HeSAtkinsonCEvansZEllettJDSouthwoodMElvingtonAChavinKDTomlinsonSA role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injuryJ Immunol20091834764477219752222 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="84450" pm="."><plain>8PritchardMTMcMullenMRStavitskyABCohenJILinFEdward MedofMNagyLEDifferential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in miceGastroenterology20071321117112617383432 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="84451" pm="."><plain>9StewartSJonesDDayCPAlcoholic liver disease: new insights into mechanisms and preventative strategiesTrends Mol Med2001740841311530336 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="84452" pm="."><plain>10JärveläinenHAVäkeväALindrosKOMeriSActivation of complement components and reduced regulator expression in alcohol-induced liver injury in the ratClin Immunol2002105576312483994 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="84453" pm="."><plain>11BykovIJunnikkalaSPeknaMLindrosKOMeriSComplement C3 contributes to ethanol-induced liver steatosis in miceAnn Med20063828028616754259 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="84454" pm="."><plain>12CohenJIRoychowdhurySDiBelloPMJacobsenDWNagyLEExogenous thioredoxin prevents ethanol-induced oxidative damage and apoptosis in mouse liverHepatology2009491709171719205032 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="84455" pm="."><plain>13CohenJIRoychowdhurySMcMullenMRStavitskyABNagyLEComplement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in miceGastroenterology2010139664674, 674.e120416309 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="84456" pm="."><plain>14OrmanESOdenaGBatallerRAlcoholic liver disease: pathogenesis, management, and novel targets for therapyJ Gastroenterol Hepatol201328 Suppl 1778423855300 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="84457" pm="."><plain>15ZhaoJThe metabolism and harm of alcoholKeji &amp; Shenghuo20116195198 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="84458" pm="."><plain>16KawarataniHTsujimotoTDouharaATakayaHMoriyaKNamisakiTNoguchiRYoshijiHFujimotoMFukuiHThe effect of inflammatory cytokines in alcoholic liver diseaseMediators Inflamm2013201349515624385684 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="84459" pm="."><plain>17CohenJIChenXNagyLERedox signaling and the innate immune system in alcoholic liver diseaseAntioxid Redox Signal20111552353421126203 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="84460" pm="."><plain>18LeungTMNietoNCYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver diseaseJ Hepatol20135839539822940046 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="84461" pm="."><plain>19CohenJINagyLEPathogenesis of alcoholic liver disease: interactions between parenchymal and non-parenchymal cellsJ Dig Dis2011123921091930 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="84462" pm="."><plain>20NagyLEThe Role of Innate Immunity in Alcoholic Liver DiseaseAlcohol Res20153723725026695748 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="84463" pm="."><plain>21RicklinDHajishengallisGYangKLambrisJDComplement: a key system for immune surveillance and homeostasisNat Immunol20101178579720720586 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="84464" pm="."><plain>22QinXGaoBThe complement system in liver diseases. Cell Mol Immunol20063333340 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="84466" pm="."><plain>23VieyraMBHeegerPSNovel aspects of complement in kidney injuryKidney Int20107749549920016462 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="84467" pm="."><plain>24HeWMedical immunology2010BeijingPeople’s Medical Publishing House7691 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="84468" pm="."><plain>25RoereckeMNanauRRehmJNeumanMEthnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic SteatosisEBioMedicine2016831733027428441 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="84469" pm="."><plain>26LiuLZhaoXWangQSunXXiaLWangQYangBZhangYMontgomerySMengHProsteatotic and Protective Components in a Unique Model of Fatty Liver: Gut Microbiota and Suppressed Complement SystemSci Rep201663176327550859 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="84470" pm="."><plain>27WlazloNvan GreevenbroekMMFerreiraIJansenEHFeskensEJvan der KallenCJSchalkwijkCGBravenboerBStehouwerCDActivated complement factor 3 is associated with liver fat and liver enzymes: the CODAM studyEur J Clin Invest20134367968823586841 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="84471" pm="."><plain>28CopenhaverMYuCYHoffmanRPComplement Components, C3 and C4, and the Metabolic SyndromeCurr Diabetes Rev2018 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="84472" pm="."><plain>29GuptaARezvaniRLapointeMPoursharifiPMarceauPTiwariSTchernofACianfloneKDownregulation of complement C3 and C3aR expression in subcutaneous adipose tissue in obese womenPLoS One20149e9547824743347 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="84473" pm="."><plain>30MaslowskaMWangHWCianfloneKNovel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidenceVitam Horm20057030933215727809 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="84474" pm="."><plain>31KalantDPhélisSFieldingBAFraynKNCianfloneKSnidermanADIncreased postprandial fatty acid trapping in subcutaneous adipose tissue in obese womenJ Lipid Res2000411963196811108729 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="84475" pm="."><plain>32Bavia L, de Castro ÍA, Massironi SM, Isaac LBasal physiological parameters of two congenic mice strains: C5 deficient C57BL/6 and C5 sufficient A/JImmunol Lett2014159475424607390 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="84476" pm="."><plain>33Bavia L, de Castro ÍA, Isaac LC57BL/6 and A/J Mice Have Different Inflammatory Response and Liver Lipid Profile in Experimental Alcoholic Liver DiseaseMediators Inflamm2015201549164126448681 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="84477" pm="."><plain>34ShiWZhuQGuJLiuXLuLQianXShenJZhangFLiGAnti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolismClin Dev Immunol2013201325304624396389 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="84478" pm="."><plain>35HuXWangYHaoLYLiuXLeschCASanchezBMWendlingJMMorganRWAicherTDCarterLLCorrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonistsNat Chem Biol201511741 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="84479" pm="."><plain>36PaïdassiHTacnet-DelormePGarlattiVDarnaultCGhebrehiwetBGaboriaudCArlaudGJFrachetPC1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognitionJ Immunol20081802329233818250442 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="84480" pm="."><plain>37Lu JH, Teh BK, Wang Ld, Wang YN, Tan YS, Lai MC, Reid KBThe classical and regulatory functions of C1q in immunity and autoimmunityCell Mol Immunol2008592118318990 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="84481" pm="."><plain>38Bavia L, de Castro ÍA, Cogliati B, Dettoni JB, Alves VA, Isaac LComplement C5 controls liver lipid profile, promotes liver homeostasis and inflammation in C57BL/6 genetic backgroundImmunobiology201622182283226896155 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="84482" pm="."><plain>39PetrasekJBalaSCsakTLippaiDKodysKMenashyVBarrieauMMinSYKurt-JonesEASzaboGIL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in miceJ Clin Invest20121223476348922945633 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="84483" pm="."><plain>40MartinonFMayorATschoppJThe inflammasomes: guardians of the bodyAnnu Rev Immunol20092722926519302040 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="84484" pm="."><plain>41MacLarenRCuiWCianfloneKAdipokines and the immune system: an adipocentric viewAdv Exp Med Biol200863212119025110 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="84485" pm="."><plain>42JiangXLCohenJINagyLEPathogenesis of Alcoholic Liver Disease:Interactions between Parenchymal and Non-parenchymal CellsWeichangbing Xue201116131134 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="84486" pm="."><plain>43LeemingDJVeidalSSKarsdalMANielsenMJTrebickaJBuskTBendtsenFKragAMøllerSPro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosisScand J Gastroenterol20155058459225639675 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="84487" pm="."><plain>44JeongWIGaoBInnate immunity and alcoholic liver fibrosisJ Gastroenterol Hepatol200823 Suppl 1S112S11818336653 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="84488" pm="."><plain>45DuddempudiATImmunology in alcoholic liver diseaseClin Liver Dis20121668769823101977 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="84489" pm="."><plain>46BaumannMWitzkeOCanbayAPatschanSTreichelUGerkenGPhilippTKribbenASerum C3 complement concentrations correlate with liver function in patients with liver cirrhosisHepatogastroenterology2004511451145315362774 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="84490" pm="."><plain>47ChongWPToYFIpWKYuenMFPoonTPWongWHLaiCLLauYLMannose-binding lectin in chronic hepatitis B virus infectionHepatology2005421037104516231358 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="84491" pm="."><plain>48KarkampounaSTen DijkePDooleySJulioMKTGFβ signaling in liver regenerationCurr Pharm Des2012184103411322630085 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="84492" pm="."><plain>49HillebrandtSWasmuthHEWeiskirchenRHellerbrandCKeppelerHWerthASchirin-SokhanRWilkensGGeierALorenzenJComplement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humansNat Genet20053783584315995705 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="84493" pm="."><plain>50DeaciucIVFortunatoFD’SouzaNBHillDBMcClainCJChronic alcohol exposure of rats exacerbates apoptosis in hepatocytes and sinusoidal endothelial cellsHepatol Res20011930632411251313 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="84494" pm="."><plain>51MillerAMWangHParkOHoriguchiNLafdilFMukhopadhyayPMohAFuXYKunosGPacherPAnti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injuryAlcohol Clin Exp Res20103471972520102572 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="84495" pm="."><plain>52BajtayZJózsiMBánkiZThielSThielensNErdeiAMannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophagesEur J Immunol2000301706171310898508 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="84496" pm="."><plain>53RoychowdhurySMcMullenMRPritchardMTHiseAGvan RooijenNMedofMEStavitskyABNagyLEAn early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in miceHepatology2009491326133419133650 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="84497" pm="."><plain>54DuffieldJSForbesSJConstandinouCMClaySPartolinaMVuthooriSWuSLangRIredaleJPSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repairJ Clin Invest2005115566515630444 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="84498" pm="."><plain>55FallowfieldJAMizunoMKendallTJConstandinouCMBenyonRCDuffieldJSIredaleJPScar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosisJ Immunol20071785288529517404313 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="84499" pm="."><plain>56NietoNOxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cellsHepatology2006441487150117133487 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="84500" pm="."><plain>57Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne MCRIg: a macrophage complement receptor required for phagocytosis of circulating pathogensCell200612491592716530040 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="84501" pm="."><plain>58HinglaisNKazatchkineMDMandetCAppayMDBarietyJHuman liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical studyLab Invest1989615095142478758 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="84503" pm="."><plain>59KumarVAliSRKonradSZwirnerJVerbeekJSSchmidtREGessnerJECell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in miceJ Clin Invest200611651252016453025 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="84504" pm="."><plain>60SchieferdeckerHLRothermelETimmermannAGötzeOJungermannKAnaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liverFEBS Lett19974063053099136907 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="84505" pm="."><plain>61SchlafGSchmitzMHeineIDembergTSchieferdeckerHLGötzeOUpregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cellsHistol Histopathol2004191165117415375759 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="84506" pm="."><plain>62GuoSPZhangWFGongJPResearch advance in the origin and immunological function of kupffer cellsSheng Li Ke Xue Jin Zhan201647576027424408 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="84507" pm="."><plain>63EnomotoNIkejimaKYamashinaSHiroseMShimizuHKitamuraTTakeiYSato AndNThurmanRGKupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxinAlcohol Clin Exp Res20012551S54S11410742 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="84508" pm="."><plain>64WheelerMDThurmanRGUp-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathwayJ Biol Chem20032788435844112482856 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="84509" pm="."><plain>65SchieferdeckerHLSchlafGJungermannKGötzeOFunctions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cellsInt Immunopharmacol2001146948111367531 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="84510" pm="."><plain>66ReidDTReyesJLMcDonaldBAVoTReimerRAEksteenBKupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and InflammationPLoS One201611e015952427454866 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="84511" pm="."><plain>67BarataLMiwaTSatoSKimDMohammedISongWCDeletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attackJ Immunol20131902886289523390291 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="84512" pm="."><plain>68LaskowskiJRennerBLe QuintrecMPanzerSHannanJPLjubanovicDRusevaMMBorzaDBAntonioliAHPickeringMCDistinct roles for the complement regulators factor H and Crry in protection of the kidney from injuryKidney Int20169010912227165610 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="84513" pm="."><plain>69LiuFWuLWuGWangCZhangLTomlinsonSQinXTargeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in miceAtherosclerosis201423423724324685815 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="84514" pm="."><plain>70VernonKARusevaMMCookHTBottoMMalikTHPickeringMCPartial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic MicroangiopathyJ Am Soc Nephrol2016271334134226374608 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="84515" pm="."><plain>71Medjeral-ThomasNPickeringMCThe complement factor H-related proteinsImmunol Rev201627419120127782332 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="84516" pm="."><plain>72FaberCWilliamsJJuelHBGreenwoodJNissenMHMossSEComplement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged miceInvest Ophthalmol Vis Sci2012536324633022918646 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="84517" pm="."><plain>73WilsonVDarlayRWongWWoodKMMcFarlaneJSchejbelLSchmidtIMHarrisCLTellezJHunzeEMGenotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomyAm J Kidney Dis20136297898323870792 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="84518" pm="."><plain>74SchejbelLSchmidtIMKirchhoffMAndersenCBMarquartHVZipfelPGarredPComplement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutationGenes Immun201112909921270828 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="84519" pm="."><plain>75BlackallDPMarquesMBHemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generationAm J Clin Pathol2004121 SupplS81S8815298153 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="84520" pm="."><plain>76McCulloughRLMcMullenMRSheehanMMPoulsenKLRoychowdhurySChiangDJPritchardMTCaballeriaJNagyLEComplement Factor D protects mice from ethanol-induced inflammation and liver injuryAm J Physiol Gastrointest Liver Physiol2018315G66G7929597356 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="84521" pm="."><plain>77WuGHuWShahsafaeiASongWDobarroMSukhovaGKBronsonRRShiGPRotherRPHalperinJAComplement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complexCirc Res200910455055819131645 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="84522" pm="."><plain>78WickhamSEHotzeEMFarrandAJPolekhinaGNeroTLTomlinsonSParkerMWTwetenRKMapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9J Biol Chem2011286209522096221507937 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="84523" pm="."><plain>79HuangYFedarovichATomlinsonSDaviesCCrystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complexActa Crystallogr D Biol Crystallogr20076371472117505110 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="84524" pm="."><plain>80PodackERMüller-EberhardHJBinding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement componentsJ Immunol197812110251030690431 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="84525" pm="."><plain>81McDonaldJFNelsestuenGLPotent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerizationBiochemistry199736746474739200695 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="84526" pm="."><plain>82ChuQLiuXXiangYLiuQWStudy on the structure and function of complement C3Zhongguo Mianyixue Zazhi201430549553 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="84527" pm="."><plain>83LiuQXingGComplement regulatory proteins and IgA nephropathyZhongguo Shiyong Yike201340122124 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="84528" pm="."><plain>84de HaasCJVeldkampKEPeschelAWeerkampFVan WamelWJHeeziusECPoppelierMJVan KesselKPvan StrijpJAChemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agentJ Exp Med200419968769514993252 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="84529" pm="."><plain>85FujitaEFarkasICampbellWBaranyiLOkadaHOkadaNInactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5aJ Immunol20041726382638715128829 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="84530" pm="."><plain>86GuoRFWardPARole of C5a in inflammatory responsesAnnu Rev Immunol20052382185215771587 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="84531" pm="."><plain>87NikiforovichGVBaranskiTJStructural models for the complex of chemotaxis inhibitory protein of Staphylococcus aureus with the C5a receptorBiochem Biophys Res Commun200939048148419799858 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="84532" pm="."><plain>88OttoMHawlischHMonkPNMüllerMKlosAKarpCLKöhlJC5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonismJ Biol Chem200427914215114570896 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="84533" pm="."><plain>89LiBSCuiSHLvFLChenYLiYCHuCXChenCYProtective effects of complementary peptide of anaphylatoxin C5a on lung injury of experimental sepsis mouseDisan Junyi Daxue Xuebao2006284 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="84534" pm="."><plain>90WuZLvFLvCWuYZBlocking effects of anti-sense peptide of C5a on the adhesion between pulmonary vascular endothelial cell and neutrophilZhongduo Mianyixue Zazhi2003195 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="84535" pm="."><plain>91LiLChenLZangJTangXLiuYZhangJBaiLYinQLuYChengJC3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney diseaseMetabolism20156459761025682062 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="84536" pm="."><plain>92LeeJHKimHKoJLeeYInteraction of C5 protein with RNA aptamers selected by SELEXNucleic Acids Res2002305360536812490703 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="84537" pm="."><plain>93BieseckerGDihelLEnneyKBendeleRADerivation of RNA aptamer inhibitors of human complement C5Immunopharmacology19994221923010408383 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
